As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...

TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and ...

Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

On March 13, 2026, shares of Bio-Techne closed at $51.47, down 12.68% over the past year. Generates revenue through the sale of proprietary research tools, diagnostic assays, and instruments to both ...

Bio-Techne Corp. closed 27.94% short of its 52-week high of $72.16, which the company achieved on January 22nd.

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ...

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...